|Articles|November 14, 2012
FDA Seeks More Authority Over Compounding Pharmacies
Advertisement
The Food and Drug Administration said its authority over compounding pharmacies is limited and needs to be strengthened in the wake of a multistate meningitis outbreak caused by tainted steroid injections produced by a pharmacy in Massachusetts.
The FDA has come under scrutiny for its oversight of the New England Compounding Center, the Framingham, Mass.-based compounding pharmacy that is responsible for distributing contaminated vials of preservative-free methylprednisolone acetate.
Read the full story:
Source: ModernHealthcare.com
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Amid SOHO Data, Reviewers of BTK Inhibitors in MCL Call for Trials
2
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
3
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
4
Cross-Trial Vitiligo Data: What Payers Can and Can't Compare
5